SCHEMBL4090486

SCHEMBL4090486

CC(C)(C)OC(=O)NC/C(=C\F)Cc1ccc(Cl)cc1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.52
MAPT P10636 1/20 0.43
LMNA P02545 1/20 0.43
DRD2 P14416 5/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
POLB P06746 1/20 0.40
PPARG P37231 1/20 0.40
PPARA Q07869 1/20 0.40
CACNA1B Q00975 1/20 0.39
ALDH1A1 P00352 2/20 0.39
IDO1 P14902 1/20 0.38
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 1/20 0.38
NFKB1 P19838 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4090490 1.00 GAA (0.52) GAAMAPTLMNADRD2L3MBTL1
SCHEMBL1295835 0.88 MAPT (0.42) GAAMAPTLMNAL3MBTL1PPARG
SCHEMBL1295892 0.88 CTSS (0.45) GAALMNAPOLBALDH1A1MEN1
SCHEMBL1295897 0.88 CTSS (0.45) GAALMNAPOLBALDH1A1MEN1
SCHEMBL1295834 0.88 MAPT (0.42) GAAMAPTLMNAL3MBTL1PPARG
SCHEMBL1295038 0.88 GAA (0.39) GAAMAPTL3MBTL1ALDH1A1MEN1
SCHEMBL1295040 0.88 GAA (0.39) GAAMAPTL3MBTL1ALDH1A1MEN1
SCHEMBL1296349 0.88 GAA (0.39) GAAMAPTL3MBTL1ALDH1A1MEN1
SCHEMBL1296001 0.87 GAA (0.41) GAAMAPTLMNADRD2ALDH1A1
SCHEMBL1295998 0.87 GAA (0.41) GAAMAPTLMNADRD2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090203764-A1 INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT AND PREVENTION OF DISEASES FASTRACK PHARMACEUTICALS, INC. 2009-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203764-A1 INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT AND PREVENTION OF DISEASES VCAM1, AOC3, AOC2 GAA 1702/4885MAPT 1242/4885LMNA 4139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.